Acromegaly: Next Step When Initial Somatostatin Receptor Ligand Therapy Fails to Normalize IGF-1 and GH

This protocol addresses acromegaly patients whose initial adjuvant medical therapy — a somatostatin receptor ligand (SRL) or pegvisomant — has not achieved the required biochemical targets after an adequate treatment period. It defines the escalation strategy for this specific failure scenario.

Previous Therapy & Failure Condition

Initial adjuvant medical therapy with a somatostatin receptor ligand (SRL) — octreotide LAR or lanreotide depot/autogel — or pegvisomant failed to reach the target of age-normalized serum IGF-1 and a random GH < 1.0 µg/L at 12 weeks. This incomplete biochemical response is the trigger for escalation to the current protocol.

Treatment Approach (Partial Overview)

The next step involves combination medical therapy — the current SRL is continued and a second agent is added. The full structured regimen, including agent selection and dosing guidance, is available via the link below.

Clinical Goal

Normalization of serum IGF-1 (age-adjusted), which signifies biochemical control of acromegaly.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2014-2700

We suggest addition of pegvisomant or cabergoline in a patient with inadequate response to an SRL.
In studies of patients partially controlled (incomplete GH/IGF-1 normalization) despite high-dose SRL, the addition of pegvisomant at a median dose of 60 mg weekly (range, 20–200 mg weekly, provided as a once- or twice-weekly injection) normalized IGF-1 in 95% of patients.
We suggest a biochemical target goal of an age-normalized serum IGF-1 value, which signifies control of acromegaly.

View source ↗